

Announcement of Change in Business Scheme of Insomnia Treatment QUVIVIQ®

This material is an English translation of the press release to be issued on October 1, 2024 in Japanese, and the Japanese release is given priority regarding content and interpretation.

October 1, 2024

Mochida Pharmaceutical Co., Ltd.

Mochida Pharmaceutical Co., Ltd. (Head Office: Shinjuku-ku, Tokyo; President: Naoyuki Mochida, hereinafter "Mochida") announces a change in the business scheme of insomnia treatment QUVIVIQ®.

In 2019, Mochida and Idorsia Pharmaceuticals Ltd. (Head Office: Switzerland; CEO: André C. Muller) signed an exclusive license agreement for the supply, co-development and co-marketing of QUVIVIQ® for insomnia (including related diseases), and under this agreement, Mochida and Nxera Pharma Japan Co., Ltd. (Head Office: Minato-ku, Tokyo; President: Satoshi Tanaka, hereinafter "Nxera Pharma Japan") have been jointly developing it. After receiving manufacturing and marketing approval, Mochida and Nxera Pharma Japan were supposed to co-market it, and Mochida planned to cooperate with Shionogi & Co., Ltd. (Head Office: Osaka City, Osaka; Chairman, President and CEO: Isao Teshirogi, hereinafter "Shionogi") in sales and marketing based on a sales collaboration agreement. However, Mochida has now dissolved these agreements related to QUVIVIQ® and changed its business scheme.

In the new business scheme for QUVIVIQ® in Japan, Nxera Pharma Japan will supply the product, Mochida's subsidiary Mochida Pharmaceutical Plant Co. Ltd. will be exclusively in charge of manufacturing, and Shionogi will exclusively market and distribute QUVIVIQ®. In consideration of this change in business scheme, Mochida will receive certain lump-sum payments from Nxera Pharma Japan and Shionogi. The impact on the consolidated financial results for the year ending March 2025 will be minor.

Mochida, Nxera Pharma Japan and Shionogi will continue to work towards improving the QOL of patients suffering from insomnia with QUVIVIQ®.